BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84 [Reuters]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Reuters
BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84 | Reuters Reuters Staff 1 Min Read May 10 (Reuters) - Celldex Therapeutics Inc: * CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 RESULTS * Q1 EARNINGS PER SHARE VIEW $-0.20 — THOMSON REUTERS I/B/E/S * CELLDEX - SEES CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AT MAR 31, PROCEEDS FROM SALES OF STOCK SUFFICIENT TO FUND OPERATIONS THROUGH 2020 * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $123.2 MILLION VERSUS $139.4 MILLION AS OF DEC 31, 2017 Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved.
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.MarketBeat
- Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceGlobeNewswire
- Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceGlobeNewswire
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
CLDX
Earnings
- 2/26/24 - Miss
CLDX
Sec Filings
- 3/1/24 - Form 8-K
- 3/1/24 - Form 424B5
- 2/28/24 - Form 424B5
- CLDX's page on the SEC website